16715CTP

Application No.: 08/902,692 Date of Amendment: April 14, 2009 Date of Notice of Non-

Compliant Amendment: April 6, 2009

In the claims:

1 - 48. (Canceled)

- 49. (Previously Presented) A method for treating a chemically sensitive individual having an irregular cell cycle for T lymphocytes, the method comprising the steps of:
 - (a) collecting a blood sample from the individual;
 - (b) determining an initial status of the cell cycle for T lymphocytes:
 - (c) isolating mixed T and B lymphocytes from the blood sample:
 - (d) propagating the isolated mixed T and B lymphocytes to obtain propagated lymphocytes:
 - (e) lysing the propagated lymphocytes to obtain a lysate; and
 - (f) administering the lysate to the individual.
- 50 (Previously Presented) The method according to Claim 49, wherein the step of collecting a blood sample further comprises the step of: collecting the blood sample from the individual by venipuncture in heparinized tubes.
- 51 (Previously Presented) The method according to Claim 49, wherein the step of isolating mixed T and B lymphocytes from the blood sample further comprises the steps of: separating the erythrocytes and neutrophils from the lymphocytes of the blood sample by a sodium diatrizoate and polysucrose density gradient technique to obtain a lymphocytic sample; centrifuging the lymphocytic sample; separating and combining the lymphocytic layers from the centrifuged lymphocytic sample; and washing the combined lymphocytic layers to obtain the isolated mixed T and B lymphocytes.
- 52 (Previously Presented) The method according to Claim 49, wherein the step of propagating the isolated mixed T and B lymphocytes further comprises the steps of: culturing the isolated mixed T and B lymphocytes with a cell growth medium at about 37°C

16715CIP

Application No.: 08/902,692 Date of Amendment: April 14, 2009 Date of Notice of Non-

Date of Notice of Non-Compliant Amendment: April 6, 2009

53. (Previously Presented) The method according to Claim 52, wherein the cell growth medium is supplemented with bovine calf serum.

- 54. (Previously Presented) The method according to Claim 52, wherein the step of propagating the lymphocytes further comprises the steps of: centrifuging the cultured lymphocytes; removing the supernate from the centrifuged lymphocytes; and washing the centrifuged lymphocytes in normal saline with further centrifugation to obtain the propagated lymphocytes.
- 55. (Previously Presented) The method according to Claim 49, wherein the step of lysing the propagated lymphocytes further comprises the steps of: suspending the propagated lymphocytes in normal saline solution; sonicating the suspended lymphocytes; and filtering the sonicated lymphocytes to obtain the lysate.
- 56. (Previously Presented) The method according to Claim 49, wherein the step of administering the lysate to the individual further comprises the step of: determining a therapeutic dose of the lysate by skin testing.
- 57. (Previously Presented) The method according to Claim 56, wherein the step of administering the lysate to the individual comprises the step of: injecting the individual subcutaneously with the therapeutic dose of the lysate.
- 58. (Previously Presented) The method according to Claim 57, further comprising the step of: injecting the individual subcutaneously with at least one additional therapeutic dose of the Iysate.
- 59. (Previously Presented) The method according to Claim 49, further comprising the steps of: measuring the clinical symptoms and signs of the individual before administering the lysate, and then measuring clinical symptoms and signs of the individual after administering the lysate.

Application No.: 08/902,692 16715CIP

Date of Amendment: April 14, 2009 Date of Notice of Non-

Date of Notice of Non-Compliant Amendment: April 6, 2009

60. (Previously Presented) A method for treating a chemically sensitive individual having an irregular cell cycle for T lymphocytes, the method comprising the steps of:

- collecting a blood sample from the individual by venipuncture in heparinized tubes;
- (b) determining an initial status of the cell cycle for T lymphocytes;
- (c) isolating mixed T and B lymphocytes from the blood sample by:
 - separating the erythrocytes and neutrophils from the lymphocytes of the blood sample by a sodium diatrizoate and polysucrose density gradient technique to obtain a lymphocytic sample;
 - (ii) centrifuging the lymphocytic sample;
 - separating and combining the lymphocytic layers from the centrifuged lymphocytic sample; and
 - (iv) washing the combined lymphocytic layers to obtain the isolated mixed T and B lymphocytes;
- (d) propagating the isolated mixed T and B lymphocytes to obtain propagated lymphocytes by:
 - culturing the isolated mixed T and B lymphocytes with a cell growth medium at about 37°C;
 - (ii) centrifuging the cultured lymphocytes;
 - (ii) removing the supernate from the centrifuged lymphocytes; and
 - (iv) washing the centrifuged lymphocytes in normal saline with further centrifugation to obtain the propagated lymphocytes;
- (e) lysing the propagated lymphocytes to obtain a lysate by:
 - suspending the propagated lymphocytes in normal saline solution;
 - (ii) sonicating the suspended lymphocytes; and
 - (iii) filtering the sonicated lymphocytes to obtain the lysate; and

Application No.: 08/902,692 16715CIP

Date of Amendment: April 14, 2009 Date of Notice of Non-

Compliant Amendment: April 6, 2009

(f) administering the lysate to the individual by:

- (i) determining a therapeutic dose of the lysate by skin testing; and
- (ii) injecting the individual subcutaneously with the therapeutic dose of the lysate.
- 61. (Previously Presented) The method according to Claim 60, wherein the cell growth medium is supplemented with bovine calf serum.
- 62. (Previously Presented) The method according to Claim 60, wherein the culture is monitored until the yield is approximately 5-8 x 10⁶ cells per ml.
- 63. (Previously Presented) The method according to Claim 60, wherein the step of administering the lysate to the individual further comprises the step of: injecting the individual subcutaneously with at least one additional therapeutic dose of the lysate.
- 64. (Previously Presented) The method according to Claim 60, further comprising the steps of: measuring the clinical symptoms and signs of the individual before administering the lysate, and then measuring clinical symptoms and signs of the individual after administering the lysate.

65 - 66. (Canceled).

67 (Previously Presented) A method according to Claim 49, wherein the step of determining the initial status of the cell cycle comprises the steps of: adding lysing buffer to a portion of the cell sample; adding DNA stain and RNAse to the portion of the cell sample; analyzing the portion of the DNA stained cell sample with flow cytometry to determine the DNA distribution in the cell cycle.

Canceled. 68 - 69.

Application No.: 08/902,692 16715CIP

Date of Amendment: April 14, 2009 Date of Notice of Non-

Date of Notice of Non-Compliant Amendment: April 6, 2009

70. (Previously Presented) A method for treating a chemically sensitive individual, the method comprising the steps of:

- (a) collecting a blood sample from the individual;
- (b) determining an initial status of the cell cycle for T lymphocytes;
- (c) isolating mixed T and B lymphocytes from the blood sample;
- (d) propagating the isolated mixed T and B lymphocytes to obtain propagated lymphocytes;
- (e) lysing the propagated lymphocytes to obtain a lysate; and
- (f) administering the lysate to the individual.